| Write You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > Investment Series Investor Versus Trader |
|
Write You - Investment Series Investor Versus Trader
Many people have mixed up the terms Investor and Trader to mean the same thing. They can't be more wro According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ng. It is exactly the mixing up of these 2 very important terms that led to many people starting on the wrong ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in foot in the capital markets. An Investor is a person who puts his money where it can potentially generate a r lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. eturn. He does not usually get involved in the money making process. Investors include buyers of investment re here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe al estate and buyers of funds. A Trader is a person who fights in the capital markets front line personally i d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro order to
generate equity. He is the one who personally chooses the investment instrument (e.g
option tradin ucts have become life saving products for the pharmaceutical companies who doesnt have many innovative molecules in their product pipeline and have been inc g), makes an opinion on it and executes a series of trades in order to make money out of it. Too many people easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi have mixed being a trader for being an investor. This has led to a lot of misunderstanding. The misunderstandi nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ng comes from the wide spread teaching that anyone can choose to break out of the "rat race" by choosing to be and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ an investor rather than a worker. That person then turns to exploring option trading or forex or such instrum ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi nts "as an investor" and completely finds that not everyone can excel in those areas. While it is true that a ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a nyone can be an investor by putting your money in a well diversified
portfolio, not everyone can be a succes dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod sful trader. Active trading requires far more skill and finesse to master and to make consistent money for inc cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ome replacement. This is especially true when a lot of the strategies that are available today are highly subj tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ective. However, only by being a trader will anyone be able to generate the legendary returns that they yearn t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel so much. And being a trader is exactly the hardest to do unless you have a proven system to follow or someone ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust to mentor you. Therefore, before you take the plunge into the capital markets, make sure you know what you ar y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products e really into. If you have decided to become a trader, make sure you keep your full time job while you look fo . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de r a proven system to learn. A proven system is something like the elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip uity.com/MOE_startradingsystem.htm">Star Trading System which I have followed with great success for years tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:To Market to Market: Why Content is King List Building and Article Marketing - How Does Article Marketing Fit Into Your List Building Efforts When You Find Yourself In Debt
|